Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lytix Biopharma AS ( (DE:6BG) ) has issued an announcement.
Lytix Biopharma AS has successfully completed a private placement and retail offering, raising a total of NOK 111.3 million in gross proceeds. This capital increase, involving the issuance of 102,568 new shares, has been registered with the Norwegian Register of Business Enterprises, potentially strengthening the company’s financial position and market presence in the biotech industry.
More about Lytix Biopharma AS
Lytix Biopharma AS, based in Oslo, Norway, is a clinical-stage biotech company that specializes in developing host-defense peptide-derived molecules. Its leading product, LTX-315, is an innovative oncolytic molecule designed to enhance anti-cancer immunity, with a versatile pipeline that addresses various cancer indications and therapeutic settings.
YTD Price Performance: -2.92%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €32.89M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.